BriaCell Therapeutics Corp. (BCTX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$3.08

From 52W high−74.80%

Volume59508.00

Market cap$27.81M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$3.08

From 52W high

−74.80%

Volume

59508.00

Market cap

$27.81M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

32.1

MomentumView details →

1D Return

+5.81%

YTD Return

−57.52%

SummaryUpdated Jul 1, 2026

BriaCell Therapeutics Corp. (NASDAQ:BCTX) is a Canadian immuno-oncology biotechnology company founded in 2012 and headquartered in West Vancouver, Canada. The company went public on March 14, 2012, and focuses on developing innovative immunotherapies specifically designed to treat various forms of cancer. BriaCell operates as a clinical-stage biopharmaceutical company with no current commercial products, dedicating its resources to advancing novel cancer treatment approaches through its proprietary immunotherapy platform.

Ask drillr about BriaCell Therapeutics Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−233.33%

ROA (TTM)

−162.29%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+77.07%

FCF YoY

+19.15%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+88.87%

EBITDA YoY

−0.85%

MomentumView details →

1D Return

+5.81%

YTD Return

−57.52%

1Y Return

−70.45%

RSI (14)

32.1

vs 50D SMA

−18.92%

vs 200D SMA

−20.39%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

2.76x

Quick Ratio

2.76x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.24

EPS Surprise

—

Beats (12Q)

3/12

Next Q EPS Est

—

Avg Surprise (4Q)

−2696.66%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−38.27M

Op. CF (TTM)

−31.68M

Latest newsMore news →

BriaCell Therapeutics Corp. completed a best-efforts follow-on offering of 1,449,300 common shares at $3.25 per share for gross proceeds of $4.71 million, with ThinkEquity LLC as placement agent.155d ago

Similar companies

BeyondSpring Inc.BYSI Celularity Inc.CELU Filana Therapeutics, Inc.FLNA Evaxion Biotech A/SEVAX NextCure, Inc.NXTC Adicet Bio, Inc.ACET Find similar companies →

Latest newsMore news →